Literature DB >> 11844594

Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes.

Ping Yang1, Akira Yokomizo, Henry D Tazelaar, Randolph S Marks, Timothy G Lesnick, Daniel L Miller, Jeff A Sloan, Eric S Edell, Rebecca L Meyer, James Jett, Wanguo Liu.   

Abstract

PURPOSE: Survival of lung cancer patients has been dismal. Glutathione enzymes are directly involved in the metabolism of platinum compounds, a group of important chemotherapeutic drugs in cancer treatment. We tested the hypothesis that genes encoding glutathione enzymes may predict lung cancer short-term survival.
METHODS: We studied DNA polymorphisms of 250 primary lung cancer patients at four glutathione-related loci: GSTP1, GSTM1, GSTT1 and gamma-GCS that encode glutathione-S-transferase-pi, glutathione-S-transferase-mu, glutathione-S-transferase-theta, and gamma-glutamylcysteine synthetase, respectively. Pearson's chi(2)-square tests, Kaplan-Meier survival curves, log rank tests, and Cox regression models were applied in the analysis.
RESULTS: There were 150 (60%) men and 100 (40%) women in this study. Seventeen percent of the patients had never smoked cigarettes, and 61% had stopped smoking at least 6 months prior to their lung cancer diagnosis. Among never smokers, those with null (N) or low (L) genotype experienced a better 1-year-survival rate than those with a positive (P) or high (H) genotype. Patients with P or H at two loci (PP or PH) were compared with patients with N or L at one or both loci (other). Among never smokers, 1-year-survival rates were 60-78% for patients with PP or PH genotypes compared with 89-100% for other types. The survival advantage was greater among advanced-stage patients who were NL or NN than low-stage patients. Similar results were not observed among smokers.
CONCLUSIONS: Glutathione-related genes may determine lung cancer survival. Our results, if confirmed, would suggest new directions to enhance cancer treatment, and provide easily measurable markers for clinicians to plan patient-specific therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11844594     DOI: 10.1016/s0169-5002(01)00426-3

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

1.  Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients.

Authors:  Z Sun; J Chen; J Aakre; R S Marks; Y Y Garces; R Jiang; O Idowu; J M Cunningham; Y Liu; V S Pankratz; P Yang
Journal:  Ann Oncol       Date:  2010-05-03       Impact factor: 32.976

2.  A functional trinucleotide repeat polymorphism in the 5'-untranslated region of the glutathione biosynthetic gene GCLC is associated with increased risk for lung and aerodigestive tract cancers.

Authors:  Sailendra N Nichenametla; Joshua E Muscat; Jason G Liao; Philip Lazarus; John P Richie
Journal:  Mol Carcinog       Date:  2012-05-18       Impact factor: 4.784

3.  Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.

Authors:  Ann M Moyer; Zhifu Sun; Anthony J Batzler; Liang Li; Daniel J Schaid; Ping Yang; Richard M Weinshilboum
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

Review 4.  Genetic variations underlying self-reported physical functioning: a review.

Authors:  Melissa S Y Thong; Mirjam A G Sprangers; Jeff A Sloan; Donald L Patrick; Ping Yang; Cornelis J F van Noorden
Journal:  Qual Life Res       Date:  2014-11-12       Impact factor: 4.147

5.  Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study.

Authors:  Ping Yang; Sumithra J Mandrekar; Shauna H Hillman; Katie L Allen Ziegler; Zhifu Sun; Jason A Wampfler; Julie M Cunningham; Jeff A Sloan; Alex A Adjei; Edith Perez; James R Jett
Journal:  J Thorac Oncol       Date:  2009-04       Impact factor: 15.609

6.  Association between GSTP1, GSTM1 and GSTT1 polymorphisms involved in xenobiotic metabolism and head and neck cancer development.

Authors:  Anelise Russo; Pamela Risardi Francelin; Ana Lívia Silva Galbiatti; Luis Sérgio Raposo; José Victor Maníglia; Erika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Mol Biol Rep       Date:  2013-05-10       Impact factor: 2.316

7.  Meta- and pooled analysis of GSTP1 polymorphism and lung cancer: a HuGE-GSEC review.

Authors:  Michele L Cote; Wei Chen; Daryn W Smith; Simone Benhamou; Christine Bouchardy; Dorota Butkiewicz; Kwun M Fong; Manuel Gené; Ari Hirvonen; Chikako Kiyohara; Jill E Larsen; Pinpin Lin; Ole Raaschou-Nielsen; Andrew C Povey; Edyta Reszka; Angela Risch; Joachim Schneider; Ann G Schwartz; Mette Sorensen; Jordi To-Figueras; Shinkan Tokudome; Yuepu Pu; Ping Yang; Angela S Wenzlaff; Harriet Wikman; Emanuela Taioli
Journal:  Am J Epidemiol       Date:  2009-02-24       Impact factor: 4.897

8.  Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?

Authors:  Antonis Valachis; Davide Mauri; Christodoulos Neophytou; Nikolaos P Polyzos; Lampriani Tsali; Antonios Garras; Evangelos G Papanikolau
Journal:  Int J Med Sci       Date:  2011-08-24       Impact factor: 3.738

9.  Is genetic background important in lung cancer survival?

Authors:  Linda S Lindström; Per Hall; Mikael Hartman; Fredrik Wiklund; Kamila Czene
Journal:  PLoS One       Date:  2009-05-29       Impact factor: 3.240

10.  Analysis of case-parent trios at a locus with a deletion allele: association of GSTM1 with autism.

Authors:  Steven Buyske; Tanishia A Williams; Audrey E Mars; Edward S Stenroos; Sue X Ming; Rong Wang; Madhura Sreenath; Marivic F Factura; Chitra Reddy; George H Lambert; William G Johnson
Journal:  BMC Genet       Date:  2006-02-10       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.